Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Aleksandar Skuban"'
Autor:
Mario Enrico Canonico, Judith Hsia, Nicole L. Guthrie, Martha Simmons, Prapti Mehta, Paul Lupinacci, Kate Edwards, Kara Mosesso, Michelle Gearhart, Aleksandar Skuban, Marc P. Bonaca, Mark A. Berman
Publikováno v:
Clinical Cardiology. 45:850-856
The prevalence of type 2 diabetes (T2D) continues to rise in the United States and worldwide. Cognitive behavioral therapy (CBT) has been shown to improve glycemic control in patients with T2D, but broad implementation has been limited by inherent ac
Autor:
Aleksandar Skuban, Robert D. McQuade, Raymond Sanchez, Nanco Hefting, Peter Zhang, Claudette Brewer, Mary Hobart, Mette Krog Josiassen, Carole Augustine
Publikováno v:
Current Medical Research and Opinion. 34:633-642
To assess the efficacy, safety, and tolerability of brexpiprazole as adjunctive treatment in adults with major depressive disorder (MDD) and an inadequate response to prior antidepressant treatment (ADT).Patients with a current major depressive episo
Autor:
Emmanuelle Weiller, Peter Zhang, James Craig Nelson, Catherine Weiss, Mary Hobart, Aleksandar Skuban, Michael E. Thase
Publikováno v:
Current Psychiatry Reviews. 12:278-290
Background: Many patients with major depressive disorder (MDD) do not respond adequately to first-line antidepressant treatment (ADT). Adjunctive treatment with second-generation antipsychotics has demonstrated efficacy for patients with MDD, but is
Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Autor:
Aleksandar Skuban, Michael E. Thase, Catherine Weiss, James Craig Nelson, Peter Zhang, Mary Hobart, Emmanuelle Weiller
Publikováno v:
Current Psychiatry Reviews. 12:291-301
Objective: To summarize efficacy data from two phase 2 and two phase 3 short-term, multicenter, randomized, double-blind, placebo-controlled studies of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive dis
Autor:
Aleksandar Skuban, Catherine Weiss, John M. Kane, Mary Hobart, John Ouyang, Christoph U. Correll, Emmanuelle Weiller
Publikováno v:
Schizophrenia Research. 174(1-3):93-98
Second-generation antipsychotics have demonstrated efficacy for patients with schizophrenia but are associated with wide-ranging side effects. Brexpiprazole, a serotonin-dopamine activity modulator, has demonstrated efficacy in adult patients with sc
Autor:
Mary Hobart, Claudette Brewer, Robert D. McQuade, Nanco Hefting, Peter Zhang, Raymond Sanchez, Aleksandar Skuban, Carole Augustine
Publikováno v:
The Journal of clinical psychiatry. 79(4)
Objective To assess the efficacy, safety, and tolerability of brexpiprazole as adjunct to antidepressant treatment (ADT) in adults with major depressive disorder (MDD) and inadequate response to ADTs. Methods Outpatients with inadequate response to 1
Autor:
Hans Eriksson, Aleksandar Skuban, William H. Carson, Michael E. Thase, Mary Hobart, Margaretta Nyilas, Raymond Sanchez, Robert D. McQuade, James M. Youakim, Peter Zhang
Publikováno v:
The Journal of Clinical Psychiatry. 76:1232-1240
Objective To evaluate efficacy, safety, and tolerability of brexpiprazole adjunctive to antidepressant treatments (ADTs) in patients with major depressive disorder (as defined by DSM-IV-TR criteria) with inadequate response to ADTs. Method Patients s
Autor:
Robert D. McQuade, Stephanie Pfister, Aleksandar Skuban, William H. Carson, Hans Eriksson, John M. Kane, John Ouyang, Margaretta Nyilas, Raymond Sanchez, Mary Hobart
Publikováno v:
Schizophrenia Research. 164:127-135
The objective of this study was to evaluate the efficacy, safety and tolerability of brexpiprazole versus placebo in adults with acute schizophrenia. This was a 6-week, multicenter, placebo-controlled double-blind phase 3 study. Patients with acute s
Autor:
Emmanuelle Weiller, Aleksandar Skuban, John Ouyang, Mary Hobart, Christoph U. Correll, Catherine Weiss, John M. Kane
Publikováno v:
Schizophrenia research. 190
Autor:
Yeong Wook Song, Seong Hwan Moon, Sung Won Lee, Kristel Vandormael, Seong Il Bin, Sung-Soo Kim, Seung Cheol Shim, Myung Chul Yoo, Diane M. Cukrow, Han Joo Baek, Seung Baek Kang, Wan Hee Yoo, Byung Woo Min, Yoon Je Cho, Li Yan, Aleksandar Skuban, Anish Mehta, Kyoung Ho Moon, Yong Wook Park, Dae Hyun Yoo
Publikováno v:
Current Medical Research and Opinion. 30:2399-2408
We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA).This study included patients (≥ 40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib